Breaking News Instant updates and real-time market news.

CRC

California Resources

$8.40

2.82 (50.54%)

, AM

Antero Midstream

$6.67

0.23 (3.57%)

08:45
11/04/19
11/04
08:45
11/04/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: California Resources (CRC) 13.19% +0.85, Antero Midstream (AM) 90.98% +0.52, ADT (ADT) 17.82% +0.46, iShares DJ US Home Construction Index Fund (ITB) 1.68% +0.35, B&G Foods (BGS) 3.69% +0.34, AMAG Pharmaceuticals (AMAG) 1.40% +0.22, Aurora Cannabis (ACB) 68.69% +0.19, Fastly Inc (FSLY) 59.37% +0.17, SunPower (SPWR) 0.94% +0.17, and Teladoc (TDOC) 0.68% +0.13.

CRC

California Resources

$8.40

2.82 (50.54%)

AM

Antero Midstream

$6.67

0.23 (3.57%)

ADT

ADT Inc.

$7.92

0.18 (2.33%)

ITB

iShares U.S. Home Construction ETF

$45.50

0.86 (1.93%)

BGS

B&G Foods

$16.00

0.415 (2.66%)

AMAG

Amag Pharmaceuticals

$9.95

0.25 (2.58%)

ACB

Aurora Cannabis

$3.57

-0.02 (-0.56%)

FSLY

Fastly

$20.77

0.74 (3.69%)

SPWR

SunPower

$8.82

0.06 (0.68%)

TDOC

Teladoc

$78.39

1.73 (2.26%)

  • 04

    Nov

  • 07

    Nov

  • 12

    Nov

  • 12

    Nov

  • 07

    Dec

  • 09

    Dec

CRC California Resources
$8.40

2.82 (50.54%)

08/05/19
IMPC
08/05/19
NO CHANGE
Target $20
IMPC
Outperform
California Resources price target lowered to $20 from $28 at Imperial Capital
Imperial Capital analyst Jason Wangler lowered his price target for California Resources to $20 from $28 saying the company's Q2 results were impacted by lower natural gas liquid prices. However, California Resources was able to remain near cash flow positive, adds the analyst, who keeps an Outperform rating on the shares.
05/13/19
05/13/19
UPGRADE
Target $30

Outperform
California Resources upgraded to Outperform on valuation at Raymond James
As previously reported, Raymond James upgraded California Resources to Outperform from Market Perform and $30 price target. Analyst Pavel Molchanov said regulatory fears are "overdone" and the sell-off in shares has created a "beaten-down" valuation.
05/13/19
RAJA
05/13/19
UPGRADE
RAJA
Outperform
California Resources upgraded to Outperform at Raymond James
04/12/19
GSCO
04/12/19
NO CHANGE
GSCO
Goldman downgrades California Resources, Chesapeake to Sell, upgrades Murphy
Within the Exploration and Production space, Goldman Sachs analyst Brian Singer recommends selling stocks where the valuation post recent rallies "appears at odds" with the company's competitive positioning. With that in mind, Singer downgraded both California Resources (CRC) and Chesapeake Energy (CHK) to Sell from Neutral. California Resources has a low decline rate and competitive supply cost but unfavorable debt cost that does not warrant the extent of its current valuation premium, says the analyst. For Chesapeake, Singer sees less favorable supply cost and corporate returns. The analyst also upgraded Murphy Oil (MUR) to Neutral from Sell. He believes the stock's current valuation appears more in line with its competitive positioning. Singer recommends buying "low cost oil suppliers" Encana (ECA), Parsley Energy (PE), Pioneer Natural (PXD) and EOG Resources (EOG) and Chevron (CVX).
AM Antero Midstream
$6.67

0.23 (3.57%)

08/28/19
08/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Autodesk (ADSK) downgraded to Underperform from Neutral at BofA/Merrill with analyst Kash Rangan saying while the company posted solid July quarter results, uncertainty has increased as its fiscal 2020 guidance was lowered across the board. 2. Antero Midstream (AM) downgraded to Market Perform from Outperform at Raymond James. 3. Catalent (CTLT) downgraded to Sector Weight from Overweight at KeyBanc with analyst Donald Hooker saying he believes free cash flow will be limited at 20%-30% of EBITDA due to heavy capital spending, and the company will be carrying a high debt ratio, both of which may limit flexibility. 4. Kelly Services (KELYA) downgraded to Neutral from Buy at Northcoast with analyst John Healy saying shares are approaching his liquidation value of around $26. 5. Nabors Industries (NBR), Nine Energy Services (NINE), and Quintana Energy Services (QES) downgraded to Neutral from Buy at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/01/19
MUFG
08/01/19
DOWNGRADE
Target $13
MUFG
Neutral
Antero Midstream downgraded to Neutral from Overweight at MUFG
MUFG analyst Barrett Blaschke downgraded Antero Midstream to Neutral and lowered his price target to $13 from $17 after its Q2 EBITDA miss that was driven by a "difficult commodities environment". The analyst says the management tried to keep its outlook positive by discussing its "substantial" natural gas hedges, but believes that investors will be reluctant to commit to the stock
08/28/19
RAJA
08/28/19
DOWNGRADE
RAJA
Market Perform
Antero Midstream downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst J R Weston downgraded Antero Midstream to Market Perform from Outperform without a price target.
10/03/19
JPMS
10/03/19
DOWNGRADE
Target $9
JPMS
Neutral
Antero Midstream reinstated with a Neutral rating at JPMorgan
Following a period of restriction, JPMorgan analyst Jeremy Tonet resumed coverage of Antero Midstream (AM) with a Neutral rating and a $9 price target, down from the Overweight rating and $22 price target the firm had on the stock prior to restriction. JPMorgan analyst Arun Jayaram resumed coverage of Antero Resources (AR) with an Underweight rating without a price target and Tonet said his own model feeds from the Antero Resources model, which forecasts 10% production CAGR through 2021 and flat production thereafter.
ADT ADT Inc.
$7.92

0.18 (2.33%)

05/13/19
05/13/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Deere (DE) and Titan Machinery (TITN) downgraded to Neutral from Outperform at Baird. 2. Boot Barn (BOOT) downgraded to Hold from Buy at Pivotal Research with analyst Mitch Kummetz saying he sees a less favorable risk/reward at current share levels heading into the company's results on May 16. He does not see enough room for upside to his estimates, mainly because he believes oil and gas employment is becoming a "diminishing tailwind." 3. Shopify (SHOP) downgraded to Neutral from Buy at Guggenheim with analyst Ken Wong saying he sees upside potential as limited given the stock's current valuation, which he notes has now passed previous peak levels. 4. ADT Inc. (ADT) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Toni Kaplan saying she has less confidence in the company's growth outlook following a recent AlphaWise survey conducted by the firm. 5. 51job (JOBS) downgraded to Neutral from Buy at Citi with analyst Alicia Yap saying she believes weakening operating metrics, such as a faster rate of decline for active employer count and slower rate of growth of ARPU, may be signals of challenges for online recruitment revenue growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/12/19
SBSH
03/12/19
DOWNGRADE
Target $8.25
SBSH
Neutral
ADT Inc. downgraded to Neutral from Buy at Citi
Cit downgraded ADT Inc. to Neutral from Buy and lowered its price target for the shares to $8.25 from $13. The firm sees a less certain free cash flow trajectory following ADT's Q4 results.
03/15/19
IMPC
03/15/19
NO CHANGE
Target $12
IMPC
Outperform
ADT Inc. price target lowered to $12 from $15 at Imperial Capital
Imperial Capital analyst Jeff Kessler lowered his price target for ADT Inc. to $12 from $15 saying "heavy" investment translated to reduced free cash flow guidance for 2019. The analyst, however, sees continued revenue growth for ADT and maintains an Outperform rating on the shares.
05/13/19
MSCO
05/13/19
DOWNGRADE
Target $7
MSCO
Equal Weight
ADT Inc. downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Toni Kaplan downgraded ADT Inc. (ADT) to Equal Weight from Overweight as she has less confidence in the company's growth outlook following a recent AlphaWise survey conducted by the firm. The survey showed homeowners seem as inclined to buy DIY systems as ADT systems, that more ADT customers switched to DIY providers than she would have expected and that measure of brand preference for Amazon's (AMZN) Ring and Google's (GOOG) Nest were higher than for ADT, Kaplan explains. Given that the survey leads her to fear ADT may find it difficult to defend its market share, Kaplan lowered her price target on the stock to $7 from $9.
ITB iShares U.S. Home Construction ETF
$45.50

0.86 (1.93%)

BGS B&G Foods
$16.00

0.415 (2.66%)

11/01/19
BMOC
11/01/19
NO CHANGE
Target $20
BMOC
Market Perform
B&G Foods price target lowered to $20 from $28 at BMO Capital
BMO Capital analyst Kenneth Zaslow lowered his price target on B&G Foods to $20 and kept his Market Perform rating after its Q3 earnings miss, saying the "unfavorable" tax and interest expense related items offset the beat on revenue and EBITDA. The analyst further cites the company cutting its FY19 EBITDA guidance amid "persistent" higher costs in a number of its businesses.
02/28/19
BMOC
02/28/19
NO CHANGE
Target $28
BMOC
Market Perform
B&G Foods price target lowered to $28 from $33 at BMO Capital
BMO Capital analyst Kenneth Zaslow lowered his price target on B&G Foods to $28 and kept his Market Perform rating after its Q4 earnings miss that was driven by "less pricing benefit, negative product mix, and lower realization of cost saving". The analyst adds that while the company is more focused on cost savings and the new management is more conservative on guidance, he is concerned with the potential for more aggressive pricing actions, unfavorable volume elasticity, and the possibility of acquisitions.
08/30/19
FBCO
08/30/19
NO CHANGE
FBCO
B&G Foods price target lowered to $17 from $19 at Credit Suisse
Credit Suisse analyst Robert Moskow maintained an Underperform rating on B&G Foods (BGS) and lowered his price target on shares to $17 from $19 due to concerns of weaker retail trends in the company's frozen business. The analyst noted that the company is planning to launch "a slew of new frozen products" in the second half of this year to reverse the negative trends, but this may be offset by price increases and competitor Conagra (CAG) launching new products of its own.
06/11/19
EVER
06/11/19
INITIATION
Target $25
EVER
In Line
B&G Foods initiated with an In Line at Evercore ISI
Evercore ISI analyst David Palmer started B&G Foods with an In Line rating and $25 price target.
AMAG Amag Pharmaceuticals
$9.95

0.25 (2.58%)

11/01/19
PIPR
11/01/19
NO CHANGE
Target $6
PIPR
Underweight
Amag comments on Makena don't 'square with reality,' says Piper Jaffray
Piper Jaffray analyst Christoper Raymond said he remains a seller of shares of Amag Pharmaceuticals and he keeps an Underweight rating on the stock after the company's Q3 revenue missed forecasts and it cut its FY19 outlook. The FDA is contemplating withdrawal of marketing approval for Makena, which a panel of advisors voted in favor of the agency doing, yet management continues to guide to 2020 as if the drug will remain on the market, which "doesn't square with reality," said Raymond. The analyst, who also cites Intrarosa's continued underperformance and his view that Vyleesi is "unlikely to move the needle," keeps a $6 price target on Amag shares.
10/30/19
10/30/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. GrubHub (GRUB) downgraded to Neutral from Buy at Goldman Sachs, BTIG, Mizuho, and DA Davidson, to Neutral from Outperform at Wedbush, to Market Perform from Outperform at JMP Securities and Cowen, and to Hold from Buy at Stifel. 2. Ingersoll-Rand (IR) downgraded to Hold from Buy at Deutsche Bank with analyst Nicole DeBlase saying much of the near-term merger-driven upside potential is now reflected in the share price. 3. Xerox (XRX) downgraded to Underweight from Neutral at JPMorgan with analyst Paul Coster saying the stock, which is up 74% year-to-date, is trading close to peak forward multiples for the last two years. 4. Amag Pharmaceuticals (AMAG) downgraded to Underweight from Neutral at Piper Jaffray saying an FDA panel yesterday issued a "surprisingly definitive" vote to withdraw Makena's approval. 5. Werner (WERN) downgraded to Hold from Buy at Stifel with analyst David Ross citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/30/19
PIPR
10/30/19
DOWNGRADE
Target $6
PIPR
Underweight
Amag Pharmaceuticals downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray analyst Christoper Raymond downgraded Amag Pharmaceuticals to Underweight from Neutral with a price target of $6, down from $9. The stock halted yesterday at $13.33. An FDA panel yesterday issued a "surprisingly definitive" vote to withdraw Makena's approval, Raymond tells investors in a research note. The analyst, who has long argued the totality of the data casts doubt on the clinical utility of Makena as an effective treatment for the prevention of preterm birth, assumed the FDA "could exercise flexibility if the AdCom was supportive." However, yesterday's vote provides the agency "all the cover it needs" to withdraw Makena approval. He says this, coupled with Amag's "non-trivial debt burden" and history of investing heavily in unsuccessful launches, makes it hard to justify "even a Neutral thesis."
11/04/19
LEHM
11/04/19
NO CHANGE
Target $14
LEHM
Overweight
Amag Pharmaceuticals price target lowered to $14 from $16 at Barclays
Barclays analyst Balaji Prasad lowered his price target for Amag Pharmaceuticals to $14 from $16 saying that apart from the script trends for Vyleesi, the positives "were limited" in the company's Q3. The analyst sees two broad scenarios following the FDA panel's split vote. Either the agency asks Makena to be withdrawn, which Amag will counter and it turns into a prolonged affair, or the FDA allows Makena to stay, and requests additional trials with associated cost implications, Prasad tells investors in a research note. The analyst, however, still has faith in the portfolio and keeps an Overweight rating on Amag Pharmaceuticals.
ACB Aurora Cannabis
$3.57

-0.02 (-0.56%)

10/31/19
LTCO
10/31/19
NO CHANGE
Target $29
LTCO
Buy
Cannabis sector investor sentiment is now 'very low,' says Ladenburg
After a long period of negative news flow and stock performance, sentiment in the cannabis sector is "very low," Ladenburg Thalmann analyst Glenn Mattson tells investors in a research note. After participating in a number of cannabis conferences, the analyst believes the biggest contributor to the negative backdrop has been the flat lining of growth in Canada. This is mainly a result of a poor retail footprint, only 25 stores in the nation's largest province, Ontario for instance, versus more than 300 in Alberta, according to Mattson. Adding to this negative backdrop are expectations that acquisitions done at much higher levels will lead to goodwill write-downs, adds the analyst. However, he points out that goodwill write-downs are not always viewed as a negative from a stock performance perspective. While the news flow continues to be negative, a resumption of better growth as reported by the Canadian government "holds some promise while we await Cannabis 2.0," says the analyst. 2.0 refers to the second wave of cannabis derivative products, such as edibles and beverages, that will begin to be available in Canada in December. Mattson lowered his price target for Canopy Growth (CGC) to $29 from $42, for Acreage Holdings (ACRGF) to $16 from $18, and for Aurora Cannabis (ACB) to $6 from $9. He keeps Buy ratings on all three stocks, however.
10/16/19
BOFA
10/16/19
NO CHANGE
BOFA
BofA lowers cannabis stock price targets on further sales estimate changes
Following yesterday's rally in cannabis stock's driven by Aphria's (APHA) earnings, BofA Merrill Lynch analyst Christopher Carey said he doesn't see a case for sustainable upside yet until consensus estimates are cut further, which he thinks will ensue with the calendar Q3 results from the group. The reason that industry sales could be flat to down quarter-over-quarter sector-wide is that the cannabis industry is going from a period of inventory build to one of inventory "de-load," said Carey. Given his sales estimate revisions, he has lowered his price target on Aurora Cannabis (ACB) shares to $5 from $6, cut his Canopy Growth (CGC) price target to $23 from $27, trimmed his Cronos Group (CRON) target to $13 from $16 and decreased his Hexo (HEXO) target to $2 from $2.50. Carey keeps a Buy rating on Cronos, has Neutral ratings on Aurora and Canopy and maintains an Underperform rating on Hexo.
10/14/19
MKMP
10/14/19
NO CHANGE
MKMP
Sell
Aurora Cannabis price target lowered to CAD3.50 from CAD5 at MKM Partners
MKM Partners analyst Bill Kirk lowered his price target on Aurora Cannabis to CAD3.50 and kept his Sell rating ahead of its Q1 earnings later this month. The analyst notes that the "absolute industry pricing" has softened and the company's new store openings in Ontario and Quebec are trending below expectations. Kirk contends that the sequential net sales growth assumed in Aurora Cannabis Q3 expectations is "unlikely".
10/22/19
PIPR
10/22/19
NO CHANGE
Target $12
PIPR
Overweight
Piper cuts targets in Cannabis, says Canopy and Cronos best positioned
Piper Jaffray analyst Michael Lavery revisited the four Canadian licensed producers under his coverage, namely Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON) and Tilray (TLRY). The analyst continues to believe Canopy and Cronos look best positioned. Both companies have strong cash positions to facilitate growth and have good visibility on key strategic priorities, Lavery tells investors in a research note. The analyst cut his estimates for Tilray, but he keeps an Overweight rating on the shares as he still sees growth potential in both Europe and the U.S. Lavery believes Aurora lacks visibility on key strategic growth priorities and he keeps a Neutral rating on the shares. The analyst lowered his price target for Aurora to $4 from $7, for Canopy to $36 from $40, for Cronos to $12 from $18, and for Tilray to $31 from $72.
FSLY Fastly
$20.77

0.74 (3.69%)

10/11/19
PIPR
10/11/19
DOWNGRADE
Target $24
PIPR
Neutral
Fastly downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst James Fish downgraded Fastly to Neutral from Overweight with a price target of $24, up from $21. The stock's "large out-performance" over the last few months has driven valuation towards a "fair-value," Fish tells investors in a research note. The analyst is making a valuation call as he continues to like the prospects of the business longer-term.
08/14/19
08/14/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tenet (THC) reinstated with a Neutral at Goldman Sachs. 2. WWE (WWE) initiated with a Buy at Rosenblatt. 3. iHeartMedia (IHRT) initiated with a Buy at BofA/Merrill. 4. Fastly (FSLY) initiated with an Overweight at Piper Jaffray. 5. Amarin (AMRN) initiated with an Outperform at SVB Leerink. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/14/19
PIPR
08/14/19
INITIATION
Target $21
PIPR
Overweight
Fastly initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst James Fish started Fastly with an Overweight rating and $21 price target. The company provides a CDN/edge compute platform that delivers faster and safer applications and websites to end-users, Fish tells investors in a research note. He believes Fastly will benefit from "strong, sustainable" underlying market dynamics as well as the "evolutionary shift" towards edge workloads. The analyst views the recent pullback in the shares as an attractive opportunity.
10/11/19
PIPR
10/11/19
DOWNGRADE
Target $24
PIPR
Neutral
Fastly downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst James Fish downgraded Fastly to Neutral from Overweight with a price target of $24, up from $21. The stock's "large out-performance" over the last few months has driven valuation towards a "fair-value," Fish tells investors in a research note. The analyst is making a valuation call as he continues to like the prospects of the business longer-term.
SPWR SunPower
$8.82

0.06 (0.68%)

08/01/19
FBCO
08/01/19
UPGRADE
FBCO
Outperform
SunPower upgraded to Outperform from Neutral at Credit Suisse
10/07/19
GSCO
10/07/19
NO CHANGE
GSCO
Goldman says U.S. solar makers should benefit from end of bifacial exemption
Goldman Sachs analyst Brian Lee noted that the Office of the United States Trade Representative said it will withdraw a previously granted Section 201 tariff exemption for bifacial solar panels, which he sees removing a key potential overhang for solar panel pricing and U.S. competition and also believes was unexpected by most investors. Lee thinks U.S. solar manufacturers such as First Solar (FSLR) and SunPower (SPWR) are key beneficiaries of the news, while Chinese solar panel makers with bifacial capacity expansion plans, including JinkoSolar (JKS) and Canadian Solar (CSIQ), are most likely to be negatively impacted. Lee has Buy ratings on First Solar, SunPower and Canadian Solar and a Sell rating on JinkoSolar.
10/07/19
COWN
10/07/19
NO CHANGE
Target $83
COWN
Outperform
Tariff exemption positive for First Solar, says Cowen
Cowen analyst Jeffrey Osborne said the US Trade Representative pulled the tariff exemption for bifacial solar panels which were exempt from the current 25% tariff. The analyst said he expects a favorable reaction from First Solar (FSLR) shares and to a lesser extent SunPower (SPWR). He said the sharp increase in bifacial capacity coupled with a China slowdown has pressured the shares recently but this should provided some relief. Osborne maintained his Outperform rating and $83 price target on First Solar shares.
10/30/19
CFRA
10/30/19
DOWNGRADE
CFRA
Hold
SunPower downgraded to Hold from Buy at CFRA
CFRA downgraded SunPower to Hold from Buy.
TDOC Teladoc
$78.39

1.73 (2.26%)

10/01/19
BARD
10/01/19
NO CHANGE
Target $80
BARD
Outperform
UnitedHealth continuing legacy virtual care approach to MA for now, says Baird
Baird analyst Matthew Gillmor said he had been "somewhat hopeful" that UnitedHealth (UNH) would consolidate all of its virtual health offerings with Teladoc (TDOC) in 2020, but he now understands that UnitedHealth will continue with its legacy virtual care model and vendors within its Medicare Advantage book for 2020. He still suspects that Teladoc may be in a good position to win UnitedHealth's Medicare Advantage members in future years, assuming its model covering UnitedHealth's commercial book is a success. Gillmor keeps an Outperform rating and $80 price target on Teladoc shares.
10/03/19
JPMS
10/03/19
NO CHANGE
JPMS
Overweight
Teladoc recent weakness a buying opportunity, says JPMorgan
JPMorgan analyst Lisa Gill views the recent pullback in shares of Teladoc Health (TDOC) as a buying opportunity. The stock's 15% selloff in the past eight trading days has been driven, at least in part, by the news around telehealth in UnitedHealthcare's (UNH) Medicare Advantage business, as well as lingering concerns related to potential competition, Gill tells investors in a research note. The analyst, however, continues to see a "significant amount of runway" in the telehealth market and believes Teladoc is "very well positioned as the only comprehensive virtual care delivery solution." She keeps an Overweight rating on the shares.
09/25/19
DBAB
09/25/19
NO CHANGE
DBAB
Teladoc selloff on Amazon concerns a buying opportunity, says Deutsche Bank
The market is viewing Amazon.com's (AMZN) launch of Amazon Care, a virtual healthcare provider for its Seattle-based employees, as a competitive risk for Teladoc Health (TDOC), which is a "stretch," Deutsche Bank analyst George Hill tells investors in a research note. Shares of Teladoc are down 3% to $69.07 in afternoon trading. Amazon's employees continue to have access to Teladoc's services through its partnerships with Aetna and Premera, the company's principal managed care plan vendors, says Hill. Further, the analyst believes a clinic for employees is not the same as a telemed provider. While the Amazon Care model seems like something new, it just represents an example of the on-site medical clinic strategy used by many large employers, argues Hill. The analyst views the pullback today in shares of Teladoc as a buying opportunity saying the expansion of Amazon's local clinic offering does not represent a near or medium term risk to the company's business.
10/31/19
SBSH
10/31/19
NO CHANGE
Target $93
SBSH
Buy
Teladoc short interest could drive double-digit share rally, says Citi
Teladoc shares were up 5% last night on a beat and raise quarter plus positive takeaways on the key selling season, Citi analyst Stephanie Demko tells investors in a research note. However, the analyst says Teladoc has the highest short interest in her coverage universe at 38% of float. This potentially setts the company up for a double digit stock price move tomorrow, says Demko. She raised her estimates and reiterates a Buy rating on Teladoc with a $93 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.